Endometrial Carcinomas with Intestinal-Type Metaplasia/Differentiation: Does Mismatch Repair System Defects Matter? Case Report and Systematic Review of the Literature.
endometrial carcinoma
goblet cells
intestinal
metaplasia
mismatch repair
mucinous
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Aug 2020
06 Aug 2020
Historique:
received:
28
06
2020
revised:
30
07
2020
accepted:
04
08
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
epublish
Résumé
Intestinal metaplasia/differentiation in primary endometrial carcinomas is an uncommon phenomenon, with only few cases described. We performed a systematic review of endometrial carcinomas with intestinal metaplasia/differentiation interrogating the electronic databases Pubmed, Web of Science, and Scopus, and we reported an additional case arising in a 49-year-old woman. We identified only eight patients diagnosed with endometrial carcinomas exhibiting intestinal metaplasia/differentiation, and additionally our case. Endometrial carcinomas with intestinal-type features can present in pure or mixed forms in association with usual-type endometrioid carcinomas; in mixed forms, the two neoplastic components may derive from a common neoplastic progenitor, as evidenced by the concomitant loss of MSH2 and MSH6 protein expression in our case. Disease recurrences occur in a significant fraction of the cases, including patients diagnosed in low-stage disease. Endometrial carcinomas with intestinal metaplasia/differentiation are rare and they may represent a more aggressive tumor variant, thus requiring a proper treatment despite the low-tumor stage. The ProMise classification should be performed also in these unusual tumors, since they can be associated with mismatch repair system defects.
Sections du résumé
BACKGROUND
BACKGROUND
Intestinal metaplasia/differentiation in primary endometrial carcinomas is an uncommon phenomenon, with only few cases described.
MATERIAL AND METHODS
METHODS
We performed a systematic review of endometrial carcinomas with intestinal metaplasia/differentiation interrogating the electronic databases Pubmed, Web of Science, and Scopus, and we reported an additional case arising in a 49-year-old woman.
RESULTS
RESULTS
We identified only eight patients diagnosed with endometrial carcinomas exhibiting intestinal metaplasia/differentiation, and additionally our case. Endometrial carcinomas with intestinal-type features can present in pure or mixed forms in association with usual-type endometrioid carcinomas; in mixed forms, the two neoplastic components may derive from a common neoplastic progenitor, as evidenced by the concomitant loss of MSH2 and MSH6 protein expression in our case. Disease recurrences occur in a significant fraction of the cases, including patients diagnosed in low-stage disease.
CONCLUSIONS
CONCLUSIONS
Endometrial carcinomas with intestinal metaplasia/differentiation are rare and they may represent a more aggressive tumor variant, thus requiring a proper treatment despite the low-tumor stage. The ProMise classification should be performed also in these unusual tumors, since they can be associated with mismatch repair system defects.
Identifiants
pubmed: 32781666
pii: jcm9082552
doi: 10.3390/jcm9082552
pmc: PMC7465332
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Diagn Pathol. 2013 Aug 02;8:128
pubmed: 23915109
Am J Surg Pathol. 2014 Nov;38(11):1501-9
pubmed: 25229768
Pathol Res Pract. 2017 Jan;213(1):39-44
pubmed: 27913053
Int J Gynecol Pathol. 2011 Sep;30(5):492-6
pubmed: 21804398
Mod Pathol. 2016 Jan;29 Suppl 1:S29-44
pubmed: 26715172
J Gynecol Oncol. 2020 Sep;31(5):e64
pubmed: 32808495
Am J Surg Pathol. 2018 Feb;42(2):214-226
pubmed: 29135516
Am J Surg Pathol. 2014 May;38(5):698-705
pubmed: 24451279
Gynecol Oncol. 2016 Mar;140(3):430-5
pubmed: 26691220
Gynecol Oncol. 1997 May;65(2):258-64
pubmed: 9159335
Mod Pathol. 2016 Dec;29(12):1594
pubmed: 27895324
Histopathology. 1989 Oct;15(4):431-3
pubmed: 2807198
J Gynecol Oncol. 2020 Sep;31(5):e71
pubmed: 32808498
Int J Gynecol Pathol. 2016 Jul;35(4):316-20
pubmed: 26598980
Int J Gynecol Pathol. 1998 Oct;17(4):363-7
pubmed: 9785138
Adv Anat Pathol. 2011 Nov;18(6):415-37
pubmed: 21993268
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Diagn Pathol. 2017 May 12;12(1):39
pubmed: 28494767
Open Med. 2009;3(3):e123-30
pubmed: 21603045
J Gynecol Oncol. 2020 Mar;31(2):e14
pubmed: 31912672
Histopathology. 2020 Jan;76(1):93-101
pubmed: 31846531
Am J Surg Pathol. 2020 Mar;44(3):406-419
pubmed: 31567280
Int J Gynecol Pathol. 2016 Mar;35(2):118-22
pubmed: 26535979
Gynecol Oncol Rep. 2018 Dec 21;27:46-49
pubmed: 30627614
Curr Opin Obstet Gynecol. 2015 Aug;27(4):291-6
pubmed: 26107782
Malays J Med Sci. 2007 Jan;14(1):56-61
pubmed: 22593653
Gynecol Oncol. 2016 Oct;143(1):35-39
pubmed: 27519966
Adv Anat Pathol. 2002 May;9(3):145-84
pubmed: 11981113
Am J Surg Pathol. 1983 Dec;7(8):715-29
pubmed: 6318581
Hum Pathol. 1995 Dec;26(12):1385-8
pubmed: 8522315
Mod Pathol. 2020 Jun;33(6):1172-1181
pubmed: 31932681
Appl Pathol. 1984;2(2):63-9
pubmed: 6152652